Sign in

ICUI on Nasdaq

ICU Medical

Logo: icumed.com5

Medical technology company

ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, and hemodynamic monitoring systems.3 Its shares trade on Nasdaq under the symbol ICUI.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1984Founded1

Compare with Teleflex, Insulet (United States) or Globus Medical, or pick any stock.

  • TickerICUI on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersSan Clemente1
  • Websitewww.icumed.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address951 Calle Amanecer, San Clemente, Ca 92763-62126
  • Filer categoryLarge accelerated filer6
  • LEI5493003NRW7LS2QZRH604
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O CORPORATION SERVICE COMPANY, 19808 Wilmington, United States4
  • Registered withDivision of Corporations, Department of State, 22846464

See how the biggest companies compare on our leaderboards

ICU Medical, Inc. is a medical technology company based in San Clemente, California. ICU Medical products are designed to prevent bloodstream infections and protect healthcare workers from exposure to infectious diseases or hazardous drugs. ICU Medical product line includes intravenous therapy (IV) products, pumps, needle-free vascular access devices, custom infusion sets, closed system hazardous drug handling devices and systems, sensor catheters, needle-free closed blood sampling systems, and hemodynamic monitoring systems.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

36.8%Gross margin9
1.9%Operating margin9
0.0%Net margin9
-6.3%Revenue growth, 20259
0.0%Return on equity9
0.60×Debt to equity9
$91.8MFree cash flow9

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Infusion Consumables brought in 50% of the revenue ICU Medical broke down this way in fiscal 2025.

  1. Infusion Consumables$1.1B950%up 7% from 2024
  2. Infusion Systems$684.2M931%up 5% from 2024
  3. Vital Care$437.9M920%down 37% from 2024
Products and services by year
Products and services202320242025
Infusion Consumables$969.1M$1.0B$1.1B
Infusion Systems$629.0M$652.4M$684.2M
Vital Care$661.0M$690.8M$437.9M

Regions

United States brought in 61% of the revenue ICU Medical broke down this way in fiscal 2025.

  1. United States$1.4B961%down 11% from 2024
  2. EMEA$411.7M918%up 5% from 2024
  3. APAC$232.9M910%up 0% from 2024
  4. Other foreign countries$230.6M910%up 3% from 2024
Regions by year
Regions202320242025
United States$1.4B$1.5B$1.4B
EMEA$373.6M$393.5M$411.7M
APAC$241.7M$232.8M$232.9M
Other foreign countries$203.8M$223.6M$230.6M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue63¢$1.4B
  • Research and development4¢$87.5M
  • Selling, general and admin28¢$625.2M
  • Other costs1¢$12.8M
  • Interest4¢$93.3M
  • Income tax0¢$2.4M
  • Profit0¢$732.0K

Out of $2.2B in revenue.9

Where each dollar of operating cash went, fiscal 2025

  • Capital spending49¢$88.0M
  • Share buybacks5¢$8.8M
  • Kept or used elsewhere46¢$83.0M

Out of $179.8M of cash from operations.9

Financial statements

Revenue101112139$2.2B in 2025+76% since 2019
0$1.0B$2.0B$3.0B2019: $1.3B$1.3B20192020: $1.3B$1.3B2020+0%2021: $1.3B$1.3B2021+4%2022: $2.3B$2.3B2022+73%2023: $2.3B$2.3B2023−1%2024: $2.4B$2.4B2024+5%2025: $2.2B$2.2B2025−6%
Gross profit101112139$822.0M in 2025+74% since 2019
0$250.0M$500.0M$750.0M$1.0B2019: $471.9M$471.9M20192020: $461.5M$461.5M2020−2%2021: $491.5M$491.5M2021+6%2022: $697.8M$697.8M2022+42%2023: $739.9M$739.9M2023+6%2024: $824.8M$824.8M2024+11%2025: $822.0M$822.0M2025−0%
Operating income101112139$42.8M in 2025−60% since 2019
-$50.0M0$50.0M$100.0M$150.0M2019: $107.4M$107.4M20192020: $98.2M$98.2M2020−9%2021: $123.2M$123.2M2021+26%2022: -$42.9M-$42.9M20222023: $22.8M$22.8M20232024: $43.0M$43.0M2024+88%2025: $42.8M$42.8M2025−0%
Net income101112139$732.0K in 2025−99% since 2019
-$200.0M-$100.0M0$100.0M$200.0M2019: $101.0M$101.0M20192020: $86.9M$86.9M2020−14%2021: $103.1M$103.1M2021+19%2022: -$74.3M-$74.3M20222023: -$29.7M-$29.7M2023−60%2024: -$117.7M-$117.7M2024+297%2025: $732.0K$732.0K2025

Every line of the income statement as filed: the last 3 fiscal years, latest first.9

Period ending2025-12-312024-12-312023-12-31
Revenues$2.2B$2.4B$2.3B
Cost of Goods Sold$1.4B$1.6B$1.5B
Gross profit$822.0M$824.8M$739.9M
Selling, general and administrative$625.2M$638.8M$606.7M
Research and development$87.5M$88.6M$85.3M
Restructuring, strategic transaction and integration expenses$66.5M$59.8M$41.3M
Change in fair value of contingent earn-out$0-$5.4M-$16.2M
Total operating expenses$779.2M$781.8M$717.0M
Income from operations$42.8M$43.0M$22.8M
Interest Expense, Net-$83.0M-$95.8M-$95.2M
OTHER EXPENSE, NET-$232.0K-$13.2M-$5.9M
Gain (Loss) on Disposition of Business$44.8M$0$0
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest, Total$4.4M-$66.0M-$78.3M
(Provision) benefit for income taxes-$2.4M-$51.7M$48.6M
Income (Loss) from Continuing Operations before Equity Method Investments$1.9M-$117.7M-$29.7M
Income (Loss) from Equity Method Investments-$1.2M$0$0
Net Income (Loss)$732.0K-$117.7M-$29.7M
Basic$0.03-$4.83-$1.23
Diluted$0.03-$4.83-$1.23
Basic (in shares)24.6M shares24.4M shares24.1M shares
Diluted (in shares)24.9M shares24.4M shares24.1M shares

Compare ICU Medical with another company

Corporate structure

ICU Medical sits at the top of its group. 63 entities, 31 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ICU Medical

  • ICU Medical San Clemente, California, United States
    • EXC Holding Corp. Subsidiary · Delaware, United States
    • Excelsior Medical Corporation Subsidiary · Delaware, United States
    • ICU Medical (Beijing) Co. Ltd. Subsidiary · China
    • ICU Medical (Prodotti SM) Italia S.r.l Subsidiary · Italy
    • ICU Medical (Shanghai) Co. Ltd Subsidiary · China
    • ICU Medical (SM) Limited Subsidiary · United Kingdom
    • ICU Medical 2020 Limited Subsidiary · United Kingdom
    • ICU Medical Argentina S.R.L. Subsidiary · Argentina
    • ICU Medical Aust MLA Pty Limited Subsidiary · Australia
    • ICU Medical Australia Holdings Pty Limited Subsidiary · Australia
    • ICU Medical Australia Pty Limited Subsidiary · Australia
    • ICU Medical B.V. Subsidiary · Houten, Netherlands
    • ICU Medical Bahamas, Ltd Subsidiary · Bahamas
    • ICU Medical Belgium NV Subsidiary · Belgium
    • ICU Medical Bidco Ltd Subsidiary · United Kingdom
    • ICU Medical Canada Inc. Subsidiary · Canada
    • ICU Medical Chile Limitada Subsidiary · Chile
    • ICU Medical Colombia Limitada Subsidiary · Colombia
    • ICU Medical Costa Rica, Ltd Subsidiary · Bahamas
    • ICU Medical Czech Republic A.S. Subsidiary · Czechia
    • ICU Medical Danmark ApS Subsidiary · Denmark
    • ICU Medical de Mexico, S. de R. L. de C.V. Subsidiary · Mexico
    • ICU Medical Deutschland (SM) Gmbh Subsidiary · Germany
    • ICU Medical Deutschland Holdings GmbH Subsidiary · Germany
    • ICU Medical Do Brasil Produtos Hospitalares Ltda Subsidiary · Brazil
    • and 37 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ICU Medical reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$1.1B9 Dec 31, 2025$1.0B9 Dec 31, 2024+6.0%
Accumulated depreciation$645.9M9 Dec 31, 2025$592.9M9 Dec 31, 2024+8.9%
Property and equipment, net$451.8M9 Dec 31, 2025$442.7M9 Dec 31, 2024+2.0%
Finance-lease assets$5.6M9 Dec 31, 2025$3.3M9 Dec 31, 2024+71.8%
Operating-lease assets (leased space)$54.5M9 Dec 31, 2025$53.3M9 Dec 31, 2024+2.2%

Investments

ItemLatestA year beforeChange
Marketable securities, current$013 Dec 31, 2024$501.0K13 Dec 31, 2023−100.0%
Stakes in other companies (equity method)$131.6M9 Dec 31, 2025$3.0M9 Dec 31, 2024+4231.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$1.5B9 Dec 31, 2025$1.4B9 Dec 31, 2024+4.7%
Intangible assets, net (excluding goodwill)$633.6M9 Dec 31, 2025$740.8M9 Dec 31, 2024−14.5%
Finite-lived intangibles, gross$1.3B9 Dec 31, 2025$1.2B9 Dec 31, 2024+3.0%
Accumulated amortization$654.7M9 Dec 31, 2025$516.9M9 Dec 31, 2024+26.7%
Finite-lived intangibles, net$627.4M9 Dec 31, 2025$728.4M9 Dec 31, 2024−13.9%

Inventory

ItemLatestA year beforeChange
Inventory, total$615.9M9 Dec 31, 2025$584.7M9 Dec 31, 2024+5.3%
Raw materials$265.4M9 Dec 31, 2025$265.3M9 Dec 31, 20240%
Work in process$38.1M9 Dec 31, 2025$37.5M9 Dec 31, 2024+1.5%
Finished goods$312.4M9 Dec 31, 2025$281.9M9 Dec 31, 2024+10.8%

Properties, in its own words

Our material properties used by us in connection with our corporate administrative operations, manufacturing, distribution, research and development and service centers as of December 31, 2025, are as follows:

Location · Approximate Square Footage · Primary Use · Owned/Leased

The rest of Item 2

San Clemente, California, U.S. · 39,000 · Corporate Headquarters and R&D · Owned

San Clemente, California, U.S. · 9,779 · Corporate Headquarters · Leased

San Diego, California, U.S. · 13,237 · Corporate Offices and R&D · Leased

Lake Forest, Illinois, U.S. · 54,298 · Corporate Offices · Leased

Dublin, Ohio, U.S. · 13,021 · Corporate Offices · Leased

Houten, Netherlands · 7,341 · Corporate Offices · Leased

Rydalmere, NSW Australia · 14,735 · Corporate Offices/Device Service Center · Leased

Chennai, India · 30,838 · R&D · Leased

Plymouth, Minnesota, U.S. · 19,847 · Corporate Offices · Leased

Kent, United Kingdom · 11,100 · Corporate Offices · Leased

Grasbrunn, Germany · 38,155 · Corporate Offices/Device Service Center · Leased

Ensenada, Baja California, Mexico · 265,021 · Manufacturing · Owned

Monterrey, Mexico · 100,000 · Manufacturing · Owned

La Aurora, Costa Rica · 626,869 · Manufacturing · Owned

Salt Lake City, Utah, U.S. · 440,104 · Manufacturing/Device Service Center · Owned

Dublin, Ohio, U.S. · 153,121 · Manufacturing · Owned

Gary, Indiana, U.S. · 45,416 · Manufacturing · Owned

Gary, Indiana, U.S. · 14,040 · Manufacturing/Corporate Offices · Leased

Southington, Connecticut, U.S. · 132,000 · Manufacturing · Owned

Tijuana, Mexico (multiple locations) · 243,935 · Manufacturing · Leased

Hranice, Czech Republic · 129,953 · Manufacturing · Leased

Latina, Italy · 62,441 · Manufacturing · Owned

Keene, New Hampshire, U.S. · 153,427 · Warehouse/Manufacturing · Leased

Oakdale, Minnesota, U.S. · 93,648 · Warehouse/Device Service Center - Idle · Leased

Dallas, Texas, U.S. · 610,806 · Distribution Warehouse · Leased

King of Prussia, Pennsylvania, U.S. · 105,611 · Distribution Warehouse · Owned

Santa Fe Springs, California, U.S. · 76,794 · Distribution Warehouse · Owned

Wijchen, Netherlands · 149,565 · Distribution Warehouse · Leased

Olive Branch, Mississippi, U.S. · 239,863 · Distribution Warehouse · Leased

In addition to the above, we own and lease additional office and building space, research and development, and sales and support offices primarily in North America, Europe, South America, and Asia. We believe our existing facilities, both owned and leased, are in good condition and suitable for the conduct of our business.

Item 2 of the 10-K filed Feb 19, 2026.17

The story

The company was founded in 1984 by George "Doc" Lopez, MD who developed a product known as the ClickLock to better secure IV lines.

In 2006, ICU Medical introduced its first products for oncology. The ChemoClave system from ICU Medical is a closed system transfer device (CSTD) that allows pharmacists and nurses to safely mix and administer hazardous drugs used to treat cancer patients without exposing themselves to these drugs.

ICU Medical acquired the former Abbott Laboratories Critical Care business from Hospira in 2009 following a four-year business arrangement in which ICU acted as the manufacturer of the Hospira critical care product line. In February 2017 ICU Medical also acquired the Hospira Infusion Systems business from Pfizer.

From Wikipedia’s article on ICU Medical, shared under CC BY-SA 4.0.7

Leadership

Who has led ICU Medical, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven Riggs2013–2014

Chair

  1. George A. Lopez2006–2013

President

  1. Daniel Woolson2026–now

Chief financial officer

  1. Francis J. Obrien2007–2008
  2. Scott E. Lamb2016–2020
  3. Brian Michael Bonnell2020–now

Chief operating officer

  1. Christian B. Voigtlander2018–now
1990200020102020
Board members and other officers (22)

Products and brands

ICU Medical's Neutron device aims to reduce catheter occlusion caused by external factors such as connecting and disconnecting a luer, or patient vascular pressure changes caused by coughing, sneezing, crying or vomiting.

In 2015, ICU Medical acquired Excelsior Medical Corporation, a manufacturer of healthcare devices used to disinfect and protect access into a patient's bloodstream. Acquired products included the SwabCap and SwabFlush, as well as pre-filled saline and heparin flush syringes. The total purchase price for Excelsior was $59.5 million, however ICU immediately sold the operating assets of SwabFlush and pre-filled syringe businesses to Medline Industries, Inc. for $27 million.

Oncology

ICU Medical's oncology product line is designed specifically to keep healthcare workers and patients safe from exposure to hazardous drugs. In 2012, the company introduced the Diana Hazardous drug compounding system, a user-controlled automated system that helps protect clinicians from exposure to hazardous drugs and accidental needlesticks while protecting the patient preparation from exposure to environmental contaminants.

Critical care

ICU Medical's line of critical care products provides real-time hemodynamic monitoring, blood conservation solutions, oximetry catheter technology that helps optimize oxygen supply and demand, critical care catheters with no natural rubber latex components, and hemodynamic transducer kits. In addition, ICU Medical's line of advanced sensor catheters, having no natural rubber latex components, helps keep patients safe from potentially lethal allergic reactions.

From Wikipedia’s article on ICU Medical, shared under CC BY-SA 4.0.7

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • EXC Holding Corp. Delaware8
  • Excelsior Medical Corporation Delaware8
  • ICU Medical (Beijing) Co. Ltd. China8
  • ICU Medical (Prodotti SM) Italia S.r.l Italy8
  • ICU Medical (SM) Limited United Kingdom8
  • ICU Medical (SM) Pty Ltd Australia8
  • ICU Medical (Shanghai) Co. Ltd China8
  • ICU Medical 2020 Limited United Kingdom8
  • ICU Medical Argentina S.R.L. Argentina8
  • ICU Medical Aust MLA Pty Limited Australia8
  • ICU Medical Australia Holdings Pty Limited Australia8
  • ICU Medical Australia Pty Limited Australia8
  • ICU Medical B.V. Netherlands8
  • ICU Medical Bahamas, Ltd Bahamas8
  • ICU Medical Belgium NV Belgium8
  • ICU Medical Bidco Ltd United Kingdom8
  • ICU Medical Canada Inc. Canada8
  • ICU Medical Chile Limitada Chile8
  • ICU Medical Colombia Limitada Colombia8
  • ICU Medical Costa Rica, Ltd Bahamas8
  • ICU Medical Czech Republic A.S. Czech Republic8
  • ICU Medical Danmark ApS Denmark8
  • ICU Medical Deutschland (SM) Gmbh Germany8
  • ICU Medical Deutschland Holdings GmbH Germany8
All 64 listed subsidiaries
  • ICU Medical Do Brasil Produtos Hospitalares Ltda Brazil8
  • ICU Medical Enterprise France SAS France8
  • ICU Medical Europe S.r.l. Italy8
  • ICU Medical Germany GmbH Germany8
  • ICU Medical Group Limited United Kingdom8
  • ICU Medical HIS Mexico S. de R.L. de C.V. Mexico8
  • ICU Medical Healthcare Manufacturing S.A. de C.V. Mexico8
  • ICU Medical Hong Kong Limited Hong Kong8
  • ICU Medical India LLP India8
  • ICU Medical International Limited United Kingdom8
  • ICU Medical Ireland (SM) Limited Ireland8
  • ICU Medical Ireland Limited Ireland8
  • ICU Medical Italia S.r.l. Italy8
  • ICU Medical Japan Limited Japan8
  • ICU Medical Latam LLC Delaware8
  • ICU Medical Nederland B.V. Netherlands8
  • ICU Medical Osterreich Gmbh Austria8
  • ICU Medical Peru S.R.L. Peru8
  • ICU Medical Philippines, Inc. Philippines8
  • ICU Medical Productos Farmacéuticos y Hospitalarios, S.L. Spain8
  • ICU Medical SA Pty Ltd South Africa8
  • ICU Medical Sales, Inc. Delaware8
  • ICU Medical Schweiz AG Switzerland8
  • ICU Medical Singapore Pte Ltd. Singapore8
  • ICU Medical Sverige AB Sweden8
  • ICU Medical Unlimited Company Ireland8
  • ICU Medical de Mexico, S. de R. L. de C.V. Mexico8
  • ICU UK Medical Limited United Kingdom8
  • ICU World, Inc. Delaware8
  • Izoard Sub. Inc. Delaware8
  • Medex Cardio-Pulmonary, Inc. Ohio8
  • Medical Australia Pty Limited Australia8
  • Medima s.p. z.o.o. Poland8
  • Medivet Pty Ltd Australia8
  • SI Overseas Holdings Limited United kingdom8
  • Smiths Medical (Hong Kong) Limited Hong Kong8
  • Smiths Medical (Portugal) Unipessoal Limitada Portugal8
  • Smiths Medical Espana S.L.U Spain8
  • Smiths Medical India Private Limited India8
  • Tangent Medical Technologies, Inc. Delaware8

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Aug 6, 20268-K Results of operations47
  2. May 18, 20268-K Bylaws or fiscal year changed; Shareholder vote48
  3. May 7, 20268-K Results of operations49
  4. Feb 20, 20268-K Executive or director change50
  5. Feb 19, 20268-K Results of operations51
  6. Nov 6, 20258-K Results of operations52
  7. Aug 7, 20258-K Results of operations53
  8. May 14, 20258-K Executive or director change; Shareholder vote54
  9. May 8, 20258-K Results of operations55
  10. Feb 27, 20258-K Results of operations56
  11. Nov 12, 20248-K Results of operations57
  12. Oct 2, 20248-K Executive or director change58
  13. Dec 23, 2013New chief executive Steven Riggs becomes CEO18
  14. 1984Founded Founded1

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $1.66 a share, on Nov 6, 2025.59

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results47
  2. May 7, 2026Reported quarterly or annual results49
  3. Feb 19, 2026Reported quarterly or annual results51
  4. Nov 6, 2025Reported quarterly or annual results52
  5. Aug 7, 2025Reported quarterly or annual results53
  6. May 8, 2025Reported quarterly or annual results55
  7. Feb 27, 2025Reported quarterly or annual results56
  8. Nov 12, 2024Reported quarterly or annual results57

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

322 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 36 major events, 159 insider forms, 35 large holders, 72 other. The latest 20:

  1. Sep 3, 2026144 EDGAR
  2. Sep 3, 20264 PRIMARY DOCUMENT EDGAR
  3. Sep 1, 2026144 EDGAR
  4. Sep 1, 20264 PRIMARY DOCUMENT EDGAR
  5. Aug 31, 2026144 EDGAR
  6. Aug 31, 20264 PRIMARY DOCUMENT EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 13, 2026144 EDGAR
  9. Aug 13, 20264 PRIMARY DOCUMENT EDGAR
  10. Aug 13, 2026SCHEDULE 13G/A EDGAR
  11. Aug 12, 20264 PRIMARY DOCUMENT EDGAR
  12. Aug 12, 2026144 EDGAR
  13. Aug 11, 2026144 EDGAR
  14. Aug 11, 2026144 EDGAR
  15. Aug 11, 20264 PRIMARY DOCUMENT EDGAR
  16. Aug 11, 20264 PRIMARY DOCUMENT EDGAR
  17. Aug 6, 202610-Q EDGAR
  18. Aug 6, 20268-K EDGAR
  19. Jun 1, 2026SD EDGAR
  20. May 22, 2026144 EDGAR

The 322 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

74 open-market trades by officers, directors and large owners since October 2021: 3 buys and 71 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 3, 2026Sanzone Virginia RuthVP, General CounselSale4,856$168.69$819.2KForm 4
Sep 1, 2026Bonnell Brian MichaelChief Financial OfficerSale6,381$175.00$1.1MForm 4
Aug 31, 2026Bonnell Brian MichaelChief Financial OfficerSale9,307$172.79$1.6MForm 4
Aug 13, 2026Woolson DanielVP, GM-Infusion CapitalSale5,417$181.33$982.3KForm 4
Aug 12, 2026Sousa BenChief Information OfficerSale2,250$178.32$401.2KForm 4
Aug 11, 2026Voigtlander Christian B.Chief Operating OfficerSale8,929$182.93$1.6MForm 4
Aug 11, 2026FINNEY ELISHA WDirectorSale378$182.48$69.0KForm 4
May 22, 2026Woolson DanielVP, GM-Infusion CapitalSale2,123$132.21$280.7KForm 4
May 14, 2026Sanzone Virginia RuthVP, General CounselSale2,447$124.08$303.6KForm 4
May 12, 2026Greenberg David C.DirectorSale2,424$122.91$297.9KForm 4
Nov 25, 2025Woolson DanielVP, GM-Infusion CapitalSale2,897$152.35$441.4KForm 4
Nov 11, 2025Sanzone Virginia RuthVP, General CounselSale930$142.35$132.4KForm 4
Nov 11, 2025FINNEY ELISHA WDirectorSale1,285$140.42$180.4KForm 4
Aug 27, 2025Greenberg David C.DirectorBuy1,200$126.41$151.7KForm 4
Aug 14, 2025Jain VivekChairman and CEOBuy21,929$112.83$2.5MForm 4
May 30, 2025Sanzone Virginia RuthVP, General CounselSale700$133.62$93.5KForm 4
May 28, 2025Voigtlander Christian B.Chief Operating OfficerSale4,985$128.50$640.6KForm 4
May 27, 2025Voigtlander Christian B.Chief Operating OfficerSale4,945$131.00$647.8KForm 4
May 23, 2025Voigtlander Christian B.Chief Operating OfficerSale4,959$130.00$644.7KForm 4
May 22, 2025Voigtlander Christian B.Chief Operating OfficerSale4,959$130.03$644.8KForm 4

All 74 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Vivek JainChairman of the Board and Chief Executive Officer$775.0K$6.5M71
2025Christian VoigtlanderChief Operating Officer$500.0K$4.0M71
2025Brian BonnellChief Financial Officer$475.0K$3.9M71
2025Virginia SanzoneCorporate Vice President, General Counsel$430.0K$2.8M71
2025Daniel WoolsonCorporate Vice President, General Manager - Infusion Systems$395.2K$2.1M71
2024Vivek JainChairman of the Board and Chief Executive Officer$775.0K$6.5M71
2024Christian VoigtlanderChief Operating Officer$500.0K$4.0M71
2024Brian BonnellChief Financial Officer$475.0K$4.0M71
2024Virginia SanzoneCorporate Vice President, General Counsel$430.0K$2.9M71
2024Daniel WoolsonCorporate Vice President, General Manager - Infusion Systems$375.0K$2.1M71
2023Vivek JainChairman of the Board and Chief Executive Officer$775.0K$6.8M71
2023Christian VoigtlanderChief Operating Officer$500.0K$4.4M71
2023Brian BonnellChief Financial Officer$475.0K$4.4M71
2023Virginia SanzoneCorporate Vice President, General Counsel$430.0K$2.5M71
2023Daniel WoolsonCorporate Vice President, General Manager - Infusion Systems$375.0K$2.2M71

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.3,753,409$550.2M0.0%+145,087
Jupiter Topco LLC2,781,620$407.8M0.2%New
Vanguard Portfolio Management LLC1,470,583$215.6M0.0%+32,907
Fuller & Thaler Asset Management, Inc.1,298,127$190.3M0.5%+77,588
Vanguard Capital Management LLC1,123,237$164.7M0.0%+11,362
Dimensional Fund Advisors LP1,053,476$154.4M0.0%+69,674
State Street Corp1,024,369$150.2M0.0%+56,316
Schroder Investment Management Group739,138$109.3M0.1%+37,858
Ameriprise Financial Inc689,573$101.1M0.0%+83,845
Geode Capital Management, LLC660,423$96.8M0.0%+49,204
River Road Asset Management, LLC626,290$91.8M1.0%−20,140
Citadel Advisors LLC536,225$78.6M0.0%+202,889
Neuberger Berman Group LLC451,279$66.2M0.0%+4,860
Jpmorgan Chase & Co440,468$65.3M0.0%−27,349
Goldman Sachs Group Inc417,342$61.2M0.0%+94,651
Morgan Stanley372,583$54.6M0.0%−154,259
Bank Of America Corp /de/368,754$54.1M0.0%+37,015
Toronto Dominion Bank358,023$52.5M0.1%+149,091
Charles Schwab Investment Management Inc331,052$48.5M0.0%+8,573
Nomura Asset Management International Inc.328,969$48.2M0.1%+34,650
Reinhart Partners, Llc.314,768$46.1M1.1%New
Silvercrest Asset Management Group LLC297,505$43.6M0.3%−26,171
Northern Trust Corp295,779$43.4M0.0%+2,080
Fmr LLC283,195$41.5M0.0%−29,728
Federated Hermes, Inc.243,438$35.7M0.1%−14,060

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

9 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
May 6, 2025Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+13.6%Report
Oct 31, 2024Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+37.8%Report
Feb 14, 2022Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−99.8%Report
Dec 23, 2020Gilbert Ray Cisneros, Jr.Democratic, HousePartial sale$1,001 - $15,000+130.8%Report
Dec 21, 2020Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+129.1%Report
Sep 25, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−145.1%Report
Sep 24, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$15,001 - $50,000−147.4%Report
Sep 23, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−149.1%Report
Mar 31, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−216.6%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How ICU Medical is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARICU MEDICAL INC/DE2
  • CIK0000883984
  • Employer ID (EIN)33-002269217
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company17
  • Incorporated inDelaware17
  • Fiscal year endsDecember 312
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address951 Calle Amanecer, San Clemente, CA 92763-62122
  • Phone949-366-21832
  • Shares outstanding25,007,038 as of Jul 31, 202615
  • Public float$3.2B as of Jun 30, 202517
  • AuditorDELOITTE & TOUCHE LLP, Costa Mesa, California PCAOB ID 34; it also attests to the company’s internal control over financial reporting17
  • On EDGAR sinceSep 8, 19952
  • Filings2,078 in all: 4 (1,258), 8-K (271), SC 13G/A (129), 10-Q (91), 144 (44), 4/A (41), SC 13G (36), 10-K (30)2
    All 35 form types

    DEF 14A (30), 3 (21), UPLOAD (18), CORRESP (13), S-8 (12), ARS (11), SD (10), 8-K/A (7), DEFA14A (7), SCHEDULE 13G/A (7), SC 13D/A (5), 10-K/A (4), 5 (4), SC 13D (4), 10-Q/A (3), 8-A12G/A (3), DEFR14A (3), PRE 14A (3), 8-A12G (2), NT 10-K (2), S-3ASR (2), SCHEDULE 13G (2), 3/A (1), 8-A12B (1), 8-A12B/A (1), CT ORDER (1), NT 10-Q (1)

  • Latest filingsAnnual report (10-K) Feb 19, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 2, 2026
    Latest 8-K (8-K) Aug 6, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, par value $0.10 per shareICUIThe Nasdaq Stock Market LLC

From the cover page of the 10-K filed Feb 19, 2026 (Section 12(b) of the Exchange Act).17

Risk factors and legal proceedings

The risks ICU Medical names in Item 1A of its 10-K filed Feb 19, 2026: 40 risks under these headings, as written.17

  • Market and Other External Risks
  • If we are unable to compete successfully with our competitors, we may be unable to maintain market share, in which case our sales may not grow and our profitability may be adversely affected.
  • If demand for our products were to decline significantly, we might not be able to recover the cost of our expensive automated molding and assembly equipment and tooling, which could have an adverse effect on our financial condition and results of operations.
  • Product development requires substantial investment that may be difficult for us to fund and may be challenging to recover through commercial product sales.
  • If we do not successfully develop and commercialize enhanced or new products that remain competitive with new products or alternative technologies developed by others, we could lose revenue opportunities and customers, and our ability to grow our business would be impaired.
  • Cost volatility or loss of supply of our raw materials could have an adverse effect on our profitability.
  • If we cannot obtain additional custom tooling and equipment on a timely basis to enable us to meet demand for our products, we might be unable to increase our sales or might lose customers, in which case our sales could decline.
  • Heightened inflation, higher interest rates and foreign currency rate fluctuations as a result of global macroeconomic and geopolitical conditions have had and could in the future have a material adverse effect on our operations.
  • Our operating results may be adversely affected by unfavorable economic conditions that affect our customers’ ability to buy our products and our suppliers' demand for payment terms.
  • Continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement may adversely affect our prices and volume. If we cannot reduce manufacturing costs of existing and new products to counteract such pricing pressures, our sales may not grow and our profitability may decline.
  • Disruptions at the FDA, other government agencies or notified bodies caused by funding shortages, policy changes, or personnel turnover could hinder their ability to hire, retain, or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared, approved, certified, or commercialized in a timely manner, or at all, which could negatively impact our business.
  • Failure to protect our information technology systems against security breaches, service interruptions, or misappropriation of data could disrupt operations, compromise sensitive data, and expose us to liability, possibly causing our business and reputation to suffer.
The other 29 risks
  • Our business could suffer if we lose the services of key personnel.
  • The price of our common stock has been and may continue to be highly volatile due to many factors.
  • Climate-related events and other events could harm our business.
  • The evolving and varied views on sustainability and environmental, social and governance ("ESG") initiatives could increase our costs, harm our reputation and adversely impact our financial results.
  • Business and Operating Risks
  • We derive a significant portion of our revenues from non-U.S. sales and from products manufactured at our non-U.S. facilities which are then imported to the U.S. We are therefore subject to risks of doing business in other countries, including those related to tariffs, retaliatory counter measures and further escalation of trade tensions.
  • Damage to, or interruptions at, any of our manufacturing facilities or our suppliers' facilities could impair our ability to produce our products.
  • We are dependent on single and limited source third-party suppliers, which subjects our business and results of operations to risks of supplier business interruptions, and a loss or degradation in performance in our suppliers could have an adverse effect on our business and financial condition.
  • We may not be successful in achieving expected operating efficiencies or expense reductions associated with cost reduction and restructuring efforts and may experience a decline in our profitability, business disruptions or other adverse consequences to our business as a result.
  • The agreements governing our debt contain a number of restrictive covenants which limit our flexibility in operating our business, finance future operations or pursue our business strategies.
  • Significant sales through distributors expose us to risks that could have a material effect on our results of operations.
  • Legal, Compliance, and Regulatory Risks
  • Our ability to market, distribute and sell our products in the U.S. and other countries may be adversely affected if our products fail to comply with the existing laws and regulations, and applicable requirements of the FDA, governmental agencies in other countries, and notified bodies.
  • If we or our component manufacturers fail to comply with the FDA's Quality Management System Regulation or Good Manufacturing Practice regulations or other requirements, our manufacturing operations could be interrupted, and our product sales and operating results could suffer.
  • Actual or perceived failures to comply with foreign, federal, and state data privacy and security laws, regulations and standards may adversely affect our business, operations and financial performance.
  • We are subject to certain fraud and abuse and transparency laws, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.
  • Healthcare regulation and reform measures could adversely affect our revenue and financial condition.
  • Our business could be materially and adversely affected if we fail to defend and enforce our patents or other proprietary rights, if our products are found to infringe patents or other proprietary rights owned by others or if the cost to protect our patents or other proprietary rights becomes excessive or as our patents expire.
  • The misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of these uses, any of which could be costly to our business.
  • Litigation, product liability claims or product recalls could be costly and could expose us to loss.
  • Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA and foreign regulatory authorities, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us.
  • Geographic Risks
  • Significant changes in U.S. trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico and Costa Rica, can escalate trade wars and could have a meaningful adverse effect on our results of operations.
  • Our operations may be adversely impacted by our exposure to risks related to foreign currency exchange rates.
  • International sales pose additional risks related to competition with larger international companies and established local companies and higher credit risk.
  • We are dependent on manufacturing in Mexico and could be adversely affected by that region's increased labor costs and any economic, social or political disruptions.
  • We could be adversely affected by violations of the U.S. Foreign Corrupt Practices Act and other worldwide anti-bribery laws.
  • We are subject to risks associated with doing business outside of the U.S.
  • Risks Related to our Strategic Transactions
  • If we fail to effectively complete the integration of our acquired businesses in a manner that preserves our reputation with customers and the key aspects of our corporate culture, our business, financial condition and results of operations could be harmed.
  • If we are unable to effectively manage our internal growth or growth through acquisitions of companies, assets or products, our financial performance may be adversely affected.
  • For the Smiths Medical acquisition, we incurred a substantial amount of debt to finance the cash consideration portion and certain other amounts paid in connection with the Smiths Medical acquisition, which could adversely affect our business, including by restricting our ability to engage in additional transactions or incur additional indebtedness.
  • We have and may continue to acquire businesses, form strategic alliances, enter into joint ventures or make investments in businesses or technologies. Such transactions or investments could result in unforeseen operating difficulties or expenditures and require significant management resources, charges or write-downs that could adversely impact our business and operating results.

Legal proceedings

The information required with respect to this Item 3. is discussed in Part II, Item 8. "Financial Statements and Supplementary Data" of this Annual Report on Form 10-K in Note 15. Commitments and Contingencies to the Consolidated Financial Statements.

The opening of Item 3, Legal Proceedings.17

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
    Company websiteICU Medical logo
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71